What one share of Prelude Therapeutics holds
Prelude Therapeutics Incorporated ("Prelude" or the "Company") is a precision oncology company built on a foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients.
Prelude Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.27 |
|---|---|
| Profit | −$0.72 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.40 |
| Cash and investments | $1.90 |
| Book value | $1.68 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$16.52 | $0.47 | −$15.85 | — | −$29.61 |
| 2020 | — | −$4.56 | $0.05 | −$3.75 | — | — |
| 2021 | — | −$2.43 | $0.05 | −$1.86 | — | $6.00 |
| 2022 | — | −$2.44 | $0.06 | −$1.83 | — | $4.08 |
| 2023 | — | −$2.02 | $0.06 | −$1.83 | — | $4.32 |
| 2024 | $0.09 | −$1.68 | $0.01 | −$1.37 | — | $2.38 |
| 2025 | $0.16 | −$1.29 | $0.00 | −$0.73 | — | $1.09 |
Common questions about Prelude Therapeutics
How much does one share of Prelude Therapeutics earn?
Over the last 12 months, Prelude Therapeutics lost $0.72 for each share on $0.27 of sales.
Does Prelude Therapeutics pay a dividend?
Prelude Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Prelude Therapeutics’s book value per share?
Prelude Therapeutics’s book value is $1.68 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Prelude Therapeutics have?
Each share of Prelude Therapeutics has $1.90 of cash and investments, as of June 30, 2026.
What is Prelude Therapeutics’s free cash flow per share?
−$0.40 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Prelude Therapeutics bought back shares?
Prelude Therapeutics’s share count rose about 4512% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.